The vaccine can be more easily shipped and handled than Pfizer’s, helping smaller hospitals and rural areas overcome logistical hurdles
Health officials across the U.S. are counting on the arrival of a second Covid-19 vaccine to boost scarce supplies and sidestep logistical issues encountered by the first vaccine, which began distribution this week.
The U.S. Food and Drug Administration authorized the vaccine from Moderna Inc. MRNA -2.62% on Friday after an advisory panel recommended the agency approve its use. It will join a vaccine from Pfizer Inc. PFE -0.92% and BioNTech SE BNTX -2.06% that received authorization on Dec. 11.
The green light should nearly double this month’s expected U.S. supply of Covid-19 vaccine doses and help meet a federal goal of getting a vaccine to anyone who wants one by the spring or summer of 2021. Moderna expects to add 20 million doses of its vaccine to Pfizer’s expected U.S. supply of 25 million in December.